

**A V E X A**

Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4146
Website www.avexa.com.au

ASX Release

Avexa Announces Resignation of Director

Melbourne, Australia, 17 November 2009: Avexa Limited (ASX:AVX) today announced the resignation of Mr Lawrence Gozlan from its Board of Directors.

“Due to increased commitments in my capacity as a fund manager and board member of other entities, I can no longer fulfill my obligations as a director of Avexa,” said Lawrence Gozlan, CEO and founder of Scientia Capital, a specialised global investment fund focused on life sciences. “I wish the company well in its future endeavours.”

“Lawrence has been an invaluable asset to the company,” said Nathan Drona, Chairman of Avexa. “On behalf of the board and the executive team, I would like to thank him for his insights and contributions, and wish him well.”

About Avexa:

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialization of small molecules for the treatment of infectious diseases. Avexa has a pipeline of products that include apricitabine (ATC), an HIV integrase program, an HCV polymerase program and an antibiotic program for antibiotic-resistant bacterial infections.

For more information:

Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

www.avexa.com.au

For personal use only